GV has invested in Ventus Therapeutics, an immunotherapy developer co-founded by faculty from multiple academic institutions.
GV, an early-stage corporate venturing unit of internet and technology conglomerate Alphabet, backed a $60m series A round for Canada-based immunotherapy developer Ventus Therapeutics yesterday.
The round was led by venture capital firm Versant Ventures, Ventus’s founding investor, although details of its earlier contribution could not be ascertained.
Ventus Therapeutics is working on small molecule drugs for cancer and autoimmune diseases that work by interacting with the body’s innate immunity, mechanisms which become active only once a foreign…
